The $130 low and $185 high are shown on stockanalysis.com; MarketBeat-sourced search results cite a $152.43 consensus on 29 analysts while public.com/TipRanks-linked results cite averages of $167.38–$173.13 on 20–31 analysts. The disagreement reflects different analyst pools and staleness windows, and the recent wave of target cuts (JPM, MS, Citi, Mizuho, TD Cowen) means older, higher targets inflate some averages.

stockanalysis.com lists trailing P/E 24.33, forward P/E 11.69, P/B 2.35, EV/EBITDA 11.39, and TTM EPS $5.94; the Q1 2026 10-Q coverage documents the ~$3.9B unfavorable mark-to-market derivative timing effect that depresses trailing GAAP earnings.

stockanalysis.com statistics pages for both tickers, fetched July 16, 2026, show CVX at trailing P/E 31.59, forward P/E 11.39, EV/EBITDA 10.53, yield 3.92% versus XOM's 24.33 / 11.69 / 11.39 / 2.85% — both majors carry one-time-item-inflated trailing multiples.

Both aggregators independently show a Buy-tilted consensus with a large Hold contingent — Holds are the single largest bucket (12 of 24) in the stockanalysis.com panel, indicating the Street is constructive but far from unanimous.

Multiple secondary outlets report the June 16, 2026 BofA upgrade, the $154 objective, the $65/bbl Brent framing, and cited ~$3.3B of incremental Permian free cash flow at $70/bbl Brent as a supporting factor. Note the $154 target is a below-consensus, valuation-driven upgrade — only ~6.6% above the $144.51 price.

stockanalysis.com showed a previous close of $144.51 (pre-market $144.06 on July 16) with a 52-week range of $105.53–$176.41 and $598.92B market cap; JournalArta reported the July 15 close at $145.09, up 4.47%.

stockanalysis.com's statistics page fetched July 16, 2026 shows price $144.51, market cap $598.92B, enterprise value $638.14B, 4.14B shares, and +46.55% 52-week change (an intraday search quote showed $144.96 / $601.32B, consistent within a day's move).

Multiple 10-Q summaries agree on $4.18B GAAP net income / $1.00 EPS and $4.9B / $1.16 adjusted; confidence is medium because secondary sources differ slightly on revenue ($83.16B vs $85.14B) and the SEC 8-K itself could not be fetched directly (403).

Each component number (adjusted beat, FCF, buyback plan, multiples, revenue decline, payout ratio, peer comparison) is individually sourced in the findings above; this synthesizes them into balanced bull/bear framing without a recommendation. Note dividend ($4.12/yr on 4.14B shares ≈ $17B) plus $20B buybacks totals ~$37B versus $18.79B TTM FCF, implying reliance on balance-sheet capacity or higher forward cash flow.

stockanalysis.com's forecast page shows a $144.51 close on Jul 15, 2026 and an average target of $168.1 (+16.32%), median $168, high $185 (+28.02%), low $130 (-10.04%) across 24 analysts. This is a secondary aggregator; target averages vary by tracker (TipRanks and MarketBeat show averages between roughly $152 and $173 depending on analyst pool).

GuruFocus reports the Morgan Stanley Overweight/$168 action dated June 29, 2026; stockanalysis.com lists JPMorgan's Buy-equivalent $158 target as of July 14, 2026, and MarketBeat-sourced coverage notes JPMorgan, Morgan Stanley, TD Cowen, Citi, and Mizuho all cut targets while mostly keeping Overweight/Buy/Neutral stances. Confidence is medium because the JPMorgan prior target ($173) comes only from secondary aggregators.

stockanalysis.com's recent-ratings table dates Wells Fargo $185 and RBC $180 to Jul 9, Mizuho $170 to Jul 13, JPMorgan $158 to Jul 14, and Goldman $157 to Jul 15, 2026; MarketBeat-linked coverage reports the Barclays $163→$182 Overweight raise and Citi's July 8 Neutral reaffirmation. Upside percentages are computed against the $144.51 Jul 15 close. Confidence is medium because all points are from secondary aggregators, and note the split: the two highest targets on the Street ($180 RBC, $170 Mizuho) carry Hold ratings while lower targets (JPM $158) carry Buy — a sign of low conviction dispersion, not a clean bull/bear divide.

Search coverage shows JPMorgan, Morgan Stanley, TD Cowen, Citi, and Mizuho all cut XOM targets while keeping Overweight/Buy/Neutral stances, and JPMorgan explicitly kept EPS estimates above Exxon's own guidance midpoint despite the cut. This synthesis is medium confidence because it aggregates several secondary sources rather than one primary tally. For the user's bottom-line framing: the bull case per the Street is valuation (BofA: downside protected even at $65 Brent; Barclays $182) and Permian FCF growth (~$3.3B incremental at $70 Brent); the bear case is that even bulls cut targets ~$10–15 on weaker oil decks and the largest rating bucket is Hold; the swing factor analysts cite is the long-term Brent assumption ($65 vs $70+/bbl) — sustained crude strength or weakness would move targets mechanically, and Q2 2026 earnings (oil-windfall-lifted per July 13 coverage) is the near-term catalyst that would confirm or refute the above-consensus EPS models.

ExxonMobil's official investor-relations release reported Q1 2026 earnings of $4.2B ($1.00 per share); aggregator coverage cited the July 31 Q2 report with ~$3.56 EPS consensus and the company's guidance that oil price moves would add $3.5–$3.9B to upstream earnings, alongside the Texas redomicile and the $20B buyback program as secondary watch items.

10-Q summaries specify the $3.88B unfavorable derivative timing effect ($3.33B within Energy Products) and $706M Middle East supply-disruption loss as identified items excluded from the $4.9B adjusted earnings; these are timing/one-off effects, not recurring operating losses.

stockanalysis.com lists FCF $18.79B, OCF $47.72B, capex $28.93B, total debt $47.66B, net debt $39.23B, dividend $4.12 (2.85% yield, 68.7% payout); Q1 filing coverage confirms the $1.03/share quarterly declaration and $20B 2026 buyback plan. No dividend cut is indicated; the $1.03 quarterly rate implies continuation of Exxon's annual raise cadence.

fullratio's XOM page (via search results) cites a 5-year average P/E of 13.29 versus the current ~24.3-24.4 trailing multiple; the direct page fetch returned 403, so the 5-year figure rests on the search excerpt rather than a verified page read, capping confidence at medium.

MarketBeat's chart/price-history data showed a 26.33% 1-year increase; stockanalysis.com confirms the $176.41 52-week high versus a current price in the mid-$140s (roughly 18% below that high). A precise 6-month return figure was not directly published in the sources reviewed.

FX Leaders' July 2 coverage tied XOM's slide toward key support to the crude retreat as the Hormuz reopening deflated the geopolitical risk premium; Traders Union noted the stock remained supported above its 200-day moving average through the pullback.

StockInvest.us identified accumulated-volume support at $137.81 and support at $136.00; Schaeffer's Investment Research noted shares were testing the 200-day moving average, a level that has historically preceded positive forward returns for the stock.

StockInvest.us cited accumulated-volume resistance at $146.44; JournalArta's July 15 analysis centered the technical battle on the $147.01 resistance level with $163.68 as the next upside reference — the July 15 close (~$145) sits just below this band.

FX Leaders reported RSI at 35.58 on July 2 (close to oversold without a confirmed reversal); Investing.com's technical page subsequently showed RSI at 67.53, rated Neutral. The two readings are different-date snapshots consistent with the sharp early-July rebound.

Investing.com listed the 20-day EMA at 143.75, 50-day EMA at 133.76, and 50-day MA at 130.05 with buy signals, and Barchart-style aggregate signals showed MACD turning positive July 7; confidence is lowered because the sources' price snapshots were taken on different dates during a fast-moving week, so exact MA values may be slightly stale.